Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Peptide Vaccine Doubles Clinical Response Rate in Advanced Melanoma

TOP - Daily published on June 3, 2011 in Skin Cancer

Patients with stage IV or locally advanced stage III cutaneous melanoma experienced higher response rates and longer progression-free survival (PFS) when treated with a gp100 vaccine and interleukin-2 than with interleukin-2 alone, in a phase 3 randomized trial. Tumors in all 185 patients expressed HLA*A0201, which allowed presentation of the peptide vaccine to T cells. The researchers concluded that their results show the potential of immune agents in combination with other treatments in this patient population.


Complete results are published in the June 2, 2011, edition of The New England Journal of Medicine (

Related Items
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Skin Cancer
Potential New Approach to Treat Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Skin Cancer
Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Skin Cancer
Immunotherapies Take Center Stage in Melanoma
F. Stephen Hodi, Jr, MD, Lynn M. Schuchter, MD, Mario Sznol, MD, Kim A Margolin, MD
TOP - August 2013 VOL 6, NO 3 published on September 5, 2013 in Skin Cancer
Recent Advances in the Treatment of Metastatic Melanoma
Megan Hagerty, PharmD, BCOP
TOP - Special Issue May 2012, Vol 5, No 3 published on May 24, 2012 in Skin Cancer
Lenalidomide Maintenance Therapy Benefits Patients With Multiple Myeloma
TOP - Daily published on May 15, 2012 in Skin Cancer
Vismodegib: A New Treatment Option for Basal Cell Carcinoma
Rhonda Williams
TOP - April 2012, Vol 5, No 2 published on April 30, 2012 in Skin Cancer
Can Aspirin Ward Off Melanoma?
TOP - Daily published on July 13, 2011 in Skin Cancer
Ipilimumab (Yervoy) Is First Melanoma Drug Approved in a Decade
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Skin Cancer
Last modified: July 22, 2021